{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T13:37:12Z","timestamp":1762177032715,"version":"build-2065373602"},"reference-count":44,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jcehepatology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical and Experimental Hepatology"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1016\/j.jceh.2017.08.003","type":"journal-article","created":{"date-parts":[[2017,9,23]],"date-time":"2017-09-23T04:42:21Z","timestamp":1506141741000},"page":"253-261","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Chronic Hepatitis C: Do Generics Work as Well as Branded Drugs?"],"prefix":"10.1016","volume":"7","author":[{"given":"Madhumita","family":"Premkumar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gagandeep S.","family":"Grover","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Radha K.","family":"Dhiman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jceh.2017.08.003_bib0005","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.jceh.2014.06.011","article-title":"Future of therapy for hepatitis C in India: a matter of accessibility and affordability?","volume":"4","author":"Dhiman","year":"2014","journal-title":"J Clin Exp Hepatol"},{"issue":"suppl 1","key":"10.1016\/j.jceh.2017.08.003_bib0010","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/jvh.12350","article-title":"Historical epidemiology of hepatitis C virus (HCV) in select countries \u2013 volume 2","volume":"22","author":"Saraswat","year":"2015","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jceh.2017.08.003_bib0015","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/S0140-6736(16)30579-7","article-title":"The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013","volume":"388","author":"Stanaway","year":"2016","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.jceh.2017.08.003_bib0020","first-page":"937A","article-title":"Disease burden of chronic hepatitis C virus (HCV) infection in India","volume":"60","author":"Puri","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.jceh.2017.08.003_bib0025","first-page":"104","article-title":"Consensus statement of HCV task force of the Indian National Association for Study of the Liver (INASL). Part I: Status report of HCV infection in India","volume":"4","author":"Puri","year":"2014","journal-title":"J Clin Exp Hepatol"},{"key":"10.1016\/j.jceh.2017.08.003_bib0030","doi-asserted-by":"crossref","first-page":"e1002032","DOI":"10.1371\/journal.pmed.1002032","article-title":"Prices, costs, and affordability of new medicines for hepatitis C in 30 countries: an economic analysis","volume":"13","author":"Iyengar","year":"2016","journal-title":"PLoS Med"},{"issue":"May","key":"10.1016\/j.jceh.2017.08.003_bib0035","article-title":"Cost-effectiveness of hepatitis C treatment using generic direct-acting antivirals available in India","author":"Aggarwal","year":"2017","journal-title":"PLOS ONE"},{"key":"10.1016\/j.jceh.2017.08.003_bib0040","doi-asserted-by":"crossref","first-page":"838","DOI":"10.3111\/13696998.2015.1044457","article-title":"A cost utility analysis of simeprevir used with peginterferon+ribavirin in the management of genotype 1 hepatitis C virus infection, from the perspective of the UK National Health Service","volume":"18","author":"Westerhout","year":"2015","journal-title":"J Med Econ"},{"key":"10.1016\/j.jceh.2017.08.003_bib0045","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1007\/s40273-015-0373-9","article-title":"Systematic review of modelling approaches for the cost effectiveness of hepatitis C treatment with direct-acting antivirals","volume":"34","author":"Chhatwal","year":"2016","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.jceh.2017.08.003_bib0050","doi-asserted-by":"crossref","first-page":"619","DOI":"10.7326\/M14-1313","article-title":"The cost-effectiveness of sofosbuvir-based regimens for treatment of hepatitis C virus genotype 2 or 3 infection","volume":"162","author":"Linas","year":"2015","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jceh.2017.08.003_bib0055","doi-asserted-by":"crossref","first-page":"407","DOI":"10.7326\/M14-1152","article-title":"Cost-effectiveness of novel regimens for the treatment of hepatitis C virus","volume":"162","author":"Najafzadeh","year":"2015","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jceh.2017.08.003_bib0060","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.jceh.2016.09.005","article-title":"Tackling the hepatitis C disease burden in Punjab, India","volume":"6","author":"Dhiman","year":"2016","journal-title":"J Clin Exp Hepatol"},{"key":"10.1016\/j.jceh.2017.08.003_bib0075","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1007\/s12664-016-0713-5","article-title":"Efficacy and safety of sofosbuvir-based therapy for chronic hepatitis C infection in \u201creal-life\u201d cohort","volume":"35","author":"Mehta","year":"2016","journal-title":"Indian J Gastroenterol"},{"key":"10.1016\/j.jceh.2017.08.003_bib0080","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1016\/S0140-6736(16)32051-7","article-title":"Importation of generic hepatitis C therapies: bridging the price \u2013 access gap in high-income countries","volume":"389","author":"Ghinea","year":"2017","journal-title":"Lancet"},{"issue":"September","key":"10.1016\/j.jceh.2017.08.003_bib0085","article-title":"Dual treatment with sofosbuvir plus ribavirin is as effective as triple therapy with pegylated interferon plus sofosbuvir plus ribavirin in predominant genotype 3 patients with chronic hepatitis C","author":"Satsangi","year":"2016","journal-title":"J Gastroenterol Hepatol"},{"issue":"December","key":"10.1016\/j.jceh.2017.08.003_bib0090","article-title":"Sofosbuvir plus ribavirin in treatment-na\u00efve patients with chronic hepatitis C virus genotype 1 or 3 infection in India","author":"Shah","year":"2016","journal-title":"J Viral Hepat"},{"issue":"October","key":"10.1016\/j.jceh.2017.08.003_bib0095","article-title":"Results of Sofosbuvir based combination therapy for chronic hepatitis C cohort of Indian patients in real life clinical practice","author":"Sood","year":"2016","journal-title":"J Gastroenterol Hepatol"},{"year":"2017","series-title":"MMPHCRF","author":"Dhiman","key":"10.1016\/j.jceh.2017.08.003_bib0100"},{"key":"10.1016\/j.jceh.2017.08.003_bib0105","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s12664-017-0745-5","article-title":"Experience with direct acting anti-viral agents for treating hepatitis C virus infection in renal transplant recipients","volume":"36","author":"Goel","year":"2017","journal-title":"Indian J Gastroenterol"},{"key":"10.1016\/j.jceh.2017.08.003_bib0110","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s12072-017-9794-1","article-title":"Treatment of chronic hepatitis C genotype 3 with Sofosbuvir-based therapy: a real-life study","volume":"11","author":"Sidhu","year":"2017","journal-title":"Hepatol Int"},{"key":"10.1016\/j.jceh.2017.08.003_bib0115","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/S2055-6640(20)30691-9","article-title":"Rapid reductions in prices for generic sofosbuvir and daclatasvir to treat hepatitis C","volume":"2","author":"Hill","year":"2016","journal-title":"J Virus Erad"},{"key":"10.1016\/j.jceh.2017.08.003_bib0120","first-page":"e676","article-title":"Disparity in market prices for hepatitis C virus direct-acting drugs","volume":"3","author":"Andrieux-Meyer","year":"2015","journal-title":"Lancet"},{"year":"2016","series-title":"Reviewing DAA Efficacy Managing Patient Treatment In Online Neighborhoods (REDEMPTION)","author":"Freeman","key":"10.1016\/j.jceh.2017.08.003_bib0125"},{"key":"10.1016\/j.jceh.2017.08.003_bib0130","doi-asserted-by":"crossref","first-page":"S209","DOI":"10.1016\/S0168-8278(16)01726-8","article-title":"High sustained virological response rates using generic Direct Acting Antiviral treatment for hepatitis C, imported into Australia","volume":"2","author":"Freeman","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.jceh.2017.08.003_bib0135","unstructured":"EASL press release. Low-cost generic direct-acting antiviral treatment for hepatitis C is equivalent to branded formulations: New data indicate that generics are a feasible alternative to support access to direct-acting antiviral treatment for hepatitis C sufferers. 16.04.16. http:\/\/www.eurekalert.org\/pub_releases\/2016-04\/eaft-lgd040816.php#.VxH_PRMb3Io."},{"key":"10.1016\/j.jceh.2017.08.003_bib0140","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1111\/liv.13157","article-title":"The use of generic medications for hepatitis C","volume":"36","author":"Freeman","year":"2016","journal-title":"Liver Int"},{"key":"10.1016\/j.jceh.2017.08.003_bib0145","unstructured":"FixHepC. Cure hepatitis C with sofosbuvir ledipasvir daclatasvir. http:\/\/fixhepc.com\/ Accessed 14.08.17."},{"key":"10.1016\/j.jceh.2017.08.003_bib0150","first-page":"S209","article-title":"Significant reductions in costs of generic production of sofosbuvir and daclatasvir for hepatitis C treatment in low- and middle-income countries","volume":"2","author":"Hill","year":"2016","journal-title":"J Hepatol"},{"issue":"suppl 7","key":"10.1016\/j.jceh.2017.08.003_bib0155","first-page":"21487","article-title":"Efficacy of generic direct acting antiviral treatment for hepatitis C, imported into South-East Asia and China. International Congress on Drug Therapy in HIV Infection (HIV Glasgow), Glasgow, Poster 262, 2016","volume":"19","author":"Korologou-Linden","year":"2016","journal-title":"J Int AIDS Soc"},{"issue":"suppl 7","key":"10.1016\/j.jceh.2017.08.003_bib0160","first-page":"21487","article-title":"Efficacy of generic direct acting antiviral treatment for hepatitis C, imported into Russia and Eastern Europe. International Congress on Drug Therapy in HIV Infection (HIV Glasgow), Glasgow, Poster P261, 2016","volume":"19","author":"Hill","year":"2016","journal-title":"J Int AIDS Soc"},{"key":"10.1016\/j.jceh.2017.08.003_bib0165","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1016\/j.jhep.2017.01.025","article-title":"Generic ledipasvir-sofosbuvir for patients with chronic hepatitis C: a real-life observational study","volume":"66","author":"Zeng","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.jceh.2017.08.003_bib0170","doi-asserted-by":"crossref","first-page":"e45788","DOI":"10.5812\/hepatmon.45788","article-title":"Generic direct acting antiviral treatment: the first step towards elimination of hepatitis C in Iran","volume":"17","author":"Hajarizadeh","year":"2017","journal-title":"Hepat Mon"},{"key":"10.1016\/j.jceh.2017.08.003_bib0175","doi-asserted-by":"crossref","first-page":"2659","DOI":"10.2147\/DDDT.S111496","article-title":"Very rapid virologic response and early HCV response kinetics, as quick measures to compare efficacy and guide a personalized response-guided therapy","volume":"10","author":"Yakoot","year":"2016","journal-title":"Drug Des Dev Ther"},{"key":"10.1016\/j.jceh.2017.08.003_bib0180","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1111\/apt.13923","article-title":"Sofosbuvir-based treatment regimens: real life results of 14 409 chronic HCV genotype 4 patients in Egypt","volume":"45","author":"Elsharkawy","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jceh.2017.08.003_bib0185","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.jceh.2016.10.004","article-title":"Early acute severe HCV recurrence after transplantation: from universal mortality to cure","volume":"7","author":"Wadhawan","year":"2017","journal-title":"J Clin Exp Hepatol"},{"issue":"August","key":"10.1016\/j.jceh.2017.08.003_bib0190","article-title":"Daclatasvir-Sofosbuvir for treatment of hepatitis C virus in patients with inherited bleeding disorders","author":"Mehta","year":"2017","journal-title":"Indian J Gastroenterol"},{"key":"10.1016\/j.jceh.2017.08.003_bib0195","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.jceh.2017.08.002","article-title":"Generic direct acting antivirals in treatment of chronic hepatitis c infection in patients of Thalassemia major","volume":"7","author":"Nagral","year":"2017","journal-title":"J Clin Exp Hepatol"},{"issue":"July","key":"10.1016\/j.jceh.2017.08.003_bib0200","article-title":"Directly observed therapy of sofosbuvir\/ribavirin \u00b1 peginterferon with minimal monitoring for the treatment of chronic hepatitis C in people with a history of drug use in Chennai, India (C-DOT)","author":"Solomon","year":"2017","journal-title":"Viral Hepat"},{"issue":"July","key":"10.1016\/j.jceh.2017.08.003_bib0205","article-title":"Successful treatment of chronic hepatitis C infection with directly acting antivirals in renal transplant recipients","author":"Taneja","year":"2017","journal-title":"Nephrology (Carlton)"},{"issue":"March","key":"10.1016\/j.jceh.2017.08.003_bib0210","article-title":"Sofosbuvir-based treatment is safe and effective in Indian hepatitis C patients on maintenance haemodialysis: a retrospective study","author":"Akhil","year":"2017","journal-title":"Nephrology (Carlton)"},{"issue":"2","key":"10.1016\/j.jceh.2017.08.003_bib0215","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s12664-017-0735-7","article-title":"Efficacy and safety of sofosbuvir-based regimens in chronic hepatitis C patients on dialysis","volume":"36","author":"Choudhary","year":"2017","journal-title":"Indian J Gastroenterol"},{"key":"10.1016\/j.jceh.2017.08.003_bib0220","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1177\/1545109707299856","article-title":"Generic and branded drugs for the treatment of people living with HIV\/AIDS","volume":"6","author":"Bartlett","year":"2007","journal-title":"J Int Assoc Physicians AIDS Care (Chic)"},{"key":"10.1016\/j.jceh.2017.08.003_bib0225","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1200\/JOP.2016.019737","article-title":"Journey of generic imatinib: a case study in oncology drug pricing","volume":"13","author":"Chen","year":"2017","journal-title":"J Oncol Pract"},{"key":"10.1016\/j.jceh.2017.08.003_bib0230","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1517\/13543784.2013.806482","article-title":"Review of direct-acting antiviral agents for the treatment of chronic hepatitis C","volume":"22","author":"Shah","year":"2013","journal-title":"Expert Opin Investig Drugs"}],"container-title":["Journal of Clinical and Experimental Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0973688317304346?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0973688317304346?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T06:04:41Z","timestamp":1760853881000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0973688317304346"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9]]},"references-count":44,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,9]]}},"alternative-id":["S0973688317304346"],"URL":"https:\/\/doi.org\/10.1016\/j.jceh.2017.08.003","relation":{},"ISSN":["0973-6883"],"issn-type":[{"type":"print","value":"0973-6883"}],"subject":[],"published":{"date-parts":[[2017,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chronic Hepatitis C: Do Generics Work as Well as Branded Drugs?","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical and Experimental Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jceh.2017.08.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017","name":"copyright","label":"Copyright"}]}}